Illuminating Neuroinflammatory Pathways

Investigating IL-10 Modulation of Microglial Cytokine Secretion Using R&D Systems Luminex and Simple Plex Assays

Introduction

Neuroinflammation is a hallmark of many neurodegenerative diseases, driven in large part by the persistent activation of microglia—the resident macrophages of the central nervous system. In their resting state, microglia support neuronal homeostasis; however, chronic activation promotes the release of pro-inflammatory cytokines and chemokines that contribute to neuronal damage and disease progression. Understanding the molecular mechanisms that regulate this inflammatory balance is key to identifying therapeutic strategies that can restore or maintain central nervous system health.

Interleukin-10 (IL-10) is a potent anti-inflammatory cytokine known to suppress microglial activation and shift cells toward a more regulatory, neuroprotective phenotype. While IL-10's effects have been well characterized in primary microglia, immortalized cell lines such as BV-2 cells have become increasingly valuable in vitro models for dissecting the signaling and cytokine responses underlying neuroinflammation.

Here, we use **R&D Systems™ Multiplex Assays** for Luminex® instruments and **Simple Plex™ Assays** running on the automated Ella Platform to characterize how IL-10 pretreatment modulates cytokine and chemokine secretion in BV-2 and primary mouse microglia stimulated with interferon-gamma (IFN-γ) and lipopolysaccharide (LPS). We also explore how small-molecule inhibitors targeting the NF-κB and JAK-STAT pathways alter IL-10's immunomodulatory effects. Finally, we demonstrate how the **Jess™ capillary-based Simple Western™ Platform** enables rapid mechanistic assessment of pathway activation through STAT1 and STAT3 phosphorylation analysis.

Together, these complementary assay technologies provide a robust and scalable workflow for studying neuroinflammatory signaling and cytokine modulation in microglial models.

Methods

To characterize IL-10–mediated modulation of microglial inflammatory responses, BV-2 cells and primary CD-1 mouse microglia were cultured under standard conditions and plated at equivalent densities. Cells were pretreated with recombinant mouse IL-10 prior to stimulation with IFN-γ and LPS to induce a defined inflammatory state. For pathway interrogation, BV-2 cells were additionally exposed to small-molecule inhibitors targeting NF-κB (MLN4924, cardamonin) or JAK-STAT signaling (CP-690550/tofacitinib) before IL-10 treatment and cytokine challenge.

Following stimulation, culture plates were centrifuged to remove cellular debris, and clarified supernatants were collected and stored at −80 °C until analysis. Broad cytokine and chemokine profiling was performed using the R&D Systems™ Mouse XL Cytokine Luminex® Performance Panel, with concentrations calculated from standard curves generated on a Luminex instrument.

Key targets identified in the multiplex panel—including TNF-α, IL-6, G-CSF, CCL2, CCL3, CCL4, CCL5, and IL-1ra—were subsequently quantified using Simple Plex™ Assays on the Ella™ automated platform. For mechanistic analysis, BV-2 lysates from matched treatment conditions were analyzed on the Jess™ capillary-based Simple Western™ system to measure total and phosphorylated STAT1 (Y701) and STAT3 (Y705).

Comprehensive Cytokine Profiling

Multiplex immunoassays enable broad profiling of cytokine and chemokine networks from limited sample volumes—a critical advantage when working with precious cell culture supernates. Using the **R&D Systems Mouse XL Cytokine Luminex Performance Panel** (Cat. # FCSTM20), secretion of 45 analytes was quantified from BV-2 and primary CD-1 microglia treated with IFN-γ and LPS, with or without IL-10 pretreatment.

IL-10 pretreatment attenuated the secretion of key pro-inflammatory mediators including TNF-α, IL-6, CCL5/RANTES, and G-CSF. At the same time, IL-10 increased the release of IL-1 receptor antagonist (IL-1ra)—a marker associated with the anti-inflammatory M2b microglial phenotype—as well as chemokines CCL2/MCP-1 and CCL3/MIP-1α (Figure 1). These results highlight IL-10's dual role in both suppressing inflammation and promoting resolution pathways.

Cytokine Levels Measured with R&D Systems Luminex Assay



Stimulated secretion of proinflammatory cytokines TNF-α, IL-6, MCP-1, and MIP-1α by IFN-γ and LPS treated BV-2 cells are attenuated by IL-10 pretreatment and NF-κB inhibitors. IL-10 pretreatment increased secretion of anti-inflammatory cytokine IL-1 receptor antagonist (IL-1ra/IL-1F3).



TNF-α, IL-6, MCP-1, and MIP-1α secreted by IFN-γ and LPS treated primary microglia are attenuated by IL-10 pretreatment and are not attenuated by the Jak kinase inhibitor CP 690550. IL-10 pretreatment increased secretion of anti-inflammatory cytokine IL-1 receptor antagonist (IL-1ra/IL-1F3). These data have a similar pattern to Luminex.

Figure 1. Luminex multiplex analysis shows IL-10 pretreatment suppresses pro-inflammatory cytokines (TNF-α, IL-6, CCL5, G-CSF) while elevating IL-1ra in BV-2 and primary microglia following IFN-γ/LPS stimulation.

Rapid, Quantitative Verification with Simple Plex Assays

To confirm cytokine trends observed in the 45-plex Luminex panel, key inflammatory mediators were quantified using the Simple Plex Assays on the Ella microfluidic immunoassay platform. Simple Plex assays for TNF-α, IL-6, CCL5, G-CSF, IL-1ra, CCL2, CCL3, and CCL4 provided rapid, automated quantification with high precision and minimal hands-on time.

Results from the Simple Plex Assays mirrored those from the multiplex panel, validating the suppression of TNF-α, IL-6, and CCL5 secretion by IL-10 pretreatment, alongside the upregulation of IL-1ra. With its closed-cartridge design and fully automated workflow, the Ella System simplifies cytokine measurement while maintaining high sensitivity and reproducibility across runs and users—ideal for studies requiring rapid confirmation of multiplex findings (Figure 2).

Cytokine Levels Measured by Simple Plex Immunoassay

BV-2 Cells



TNF-α, IL-6, MCP-1, and MIP-1α secreted by IFN-γ and LPS treated BV-2 cells are attenuated by IL-10 pretreatment and NF-κB inhibitors. IL-10 pretreatment increased secretion of anti-inflammatory cytokine IL-1 receptor antagonist (IL-1ra/IL-1F3). These data have similar pattern to Luminex.

Primary Microglia Cells



TNF-α, IL-6, MCP-1, and MIP-1α secreted by IFN-γ and LPS treated primary microglia are attenuated by IL-10 pretreatment and are attenuated by the Jak kinase inhibitor CP 690550. IL-10 pretreatment increased secretion of anti-inflammatory cytokine IL-1 receptor antagonist (IL-1ra/IL-1F3).

Figure 2. Cytokine secretion measured by Simple Plex Assays corroborates Luminex findings, confirming IL-10–mediated suppression of TNF-α and IL-6 and induction of IL-1ra.

Mechanistic Insights Using Small Molecule Inhibitors

To explore signaling pathways involved in IL-10–mediated modulation, BV-2 cells were pretreated with small-molecule inhibitors prior to cytokine stimulation.

- **MLN4924,** an inhibitor of the NF-κB pathway, broadly reduced cytokine secretion, including TNF-α, IL-6, and chemokines CCL2, CCL3, CCL4, and CCL5.
- **CP-690550 (tofacitinib),** a JAK1/TYK2-STAT3 pathway inhibitor, decreased STAT3 phosphorylation but did not significantly affect IL-10–dependent cytokine suppression.
- **Cardamonin,** a known NF-κB modulator, further confirmed the involvement of this pathway in the inflammatory response.

These results underscore the complex interplay between JAK-STAT and NF-κB signaling in regulating microglial activation and demonstrate how pharmacological inhibitors can be used to delineate molecular mechanisms in vitro.

Assessing STAT Pathway Activation with Simple Western Jess

Activation of STAT transcription factors is a hallmark of cytokine signaling in immune and glial cells. Using the Jess Platform, we quantified phospho-STAT1 (Y701) and phospho-STAT3 (Y705) following LPS and IFN-γ stimulation in BV-2 cells with or without IL-10 and inhibitor pretreatment.

CP 690550 Inhibits Jak-Dependent STAT1 and STAT3 Phosphorylation



CP 690550 (tofacitinib) attenuated Jak kinase-dependent STAT1 and STAT3 phosphorylation, while NF-κB pathway inhibitors MLN 4924 and Cardamonin did not.

Figure 3. Jess capillary immunoassays reveal inhibitor effects on STAT1 and STAT3 phosphorylation following IL-10 and LPS and IFN-γ treatment.

MLN4924 and CP-690550 modulated STAT phosphorylation consistent with their target pathways, demonstrating Jess as a powerful tool for mechanistic validation. Automated protein separation and immunodetection in Jess Assays deliver reproducible, quantitative data in less time than traditional Western blots—eliminating the need for gels, transfers, or manual antibody incubation (Figure 3).

Conclusion

This study highlights the utility of R&D Systems Luminex, Simple Plex, and Simple Western technologies for investigating cytokine regulation and signaling mechanisms in neuroinflammation models. IL-10 pretreatment effectively modulated inflammatory cytokine secretion and induced anti-inflammatory mediators in both BV-2 and primary mouse microglia, reflecting its critical role in maintaining central nervous system immune balance.

- **R&D Systems Multiplex Assays** provided a broad overview of cytokine and chemokine networks, enabling simultaneous measurement of 45 analytes from minimal sample volume.
- **Simple Plex Assays on the Ella Platform** offered rapid, automated validation of key cytokine trends, confirming IL-10's anti-inflammatory effects with exceptional precision and reproducibility.
- **Simple Western Jess Platform** delivered mechanistic insights into pathway modulation through quantitative assessment of STAT phosphorylation.

Together, these platforms create a streamlined, multi-modal workflow for dissecting the molecular mechanisms underlying neuroinflammation—accelerating discovery in neuroimmunology and drug development.

Learn More

Scan the QR Code or Contact:
rndsystems.com/immunoassays

References

1. Boyle, D.L. et al. *Ann. Rheum. Dis.* 74:1311 (2015).
2. Gresa-Arribas, N. et al. *PLoS ONE* 7:e45227 (2012).
3. Pattis, M.J. et al. *J. Immunol.* 189:2784 (2012).